Swiss biotechnology company Roche Group (SIX: RO, ROG) (OTCQX: RHHBY) announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Roche Digital Pathology Dx (VENTANA DP 200) system.
This enables pathologists to use digital slide images for primary diagnosis, improving healthcare efficiency and patient care, particularly in areas with limited access to specialists.
The system is designed to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.
FDA clearance marks a significant step towards routine clinical use of Roche's digital pathology solutions.
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system